Thus, inhibition of IL-4 by dupilumab may lead to enthesitis and inflammatory arthritis similar to how it occurs in spondyloarthropathy conditions such as axial spondyloarthritis and psoriatic arthritis. This evidence concerns the gene IL4 and enthesitis.